US imposes 100% tariff on patented drug imports unless co. signs drug pricing deal or agrees to make product in the US, according to White House fact sheet
- Drugmakers face 100% tariff unless they cut prices or produce drugs in the US.
- Pharmaceutical tariff reduced to 15% on Europe, Japan, South Korea, and Switzerland due to trade deals
- Tariff can be reduced to 20% if companies move manufacturing to US.
- Has made 17 pharma deals; signed 13 and negotiating remaining four.
- Large pharma companies have 120 days to make announcements to avoid 100% tariff
- Smaller pharmaceutical companies have 180 days to avoid higher tariff
- Companies that move manufacturing to the US and sign most-favored-nation drug pricing deals with US HHS are exempt from pharmaceutical tariffs
Context
The US's imposition of a 100% tariff on patented drug imports unless companies comply with pricing deals or shift production to the US marks a significant shift in drug pricing policy. This will likely create immediate pressure on pharmaceutical companies, impacting supply chains and their profitability, while potentially strengthening domestic manufacturing. Additionally, the global reaction could influence market sentiment across equities, currencies, and commodities, particularly for firms heavily reliant on drug imports.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#GEOPOLITICAL#IMPORTANT#FOREX#EQUITIES#ENERGY#METALS#US SESSION#WTI#COMMODITIES#GOLD#METALS & MINING#MATERIALS (GROUP)#BRENT CRUDE#DXY#TARIFF#TRADE